Alfaxan Multidose 4% alfaxalone Updated Nov 7
Alfaxan Multidose 4% has no scheduled regulatory decision or pivotal readout in the next 12 months. The standard 10 mg/mL formulation is already marketed. Watch for any FDA submission or label expansion for the 4% concentrated formulation, but none is currently visible. Zoetis's stock moves on company-wide earnings and its large dermatology/parasiticide portfolio, not on this single anesthetic product.
- Alfaxalone is a well-established veterinary anesthetic with a strong safety profile and is the leading anesthetic product in its class globally.
- The 4% concentrated formulation allows smaller injection volumes, which is advantageous for wildlife and exotic animal sedation where large volumes are impractical.
- Zoetis acquired Jurox (and Alfaxan) in 2022, and the product benefits from Zoetis's global commercial infrastructure and distribution network.
- The 4% concentrated formulation appears to still be in the research phase with no clear FDA submission or commercialization timeline visible.
- Alfaxan is a very small product within Zoetis's massive portfolio; Zoetis has dozens of products with over $100M in annual revenue, making Alfaxan immaterial to the stock's performance.
- Zoetis faces competitive pressure in its core dermatology franchise (Apoquel, Cytopoint), which are the real value drivers, and the company's Q3 2026 revenue declined 1% year-over-year.